

2019 EMERGING THERAPIES FOR PBC, NASH ESLD AND HCC SEMINAR SERIES

Denver, CO – June 22, 2019

Conference Location	Embassy Suites Denver Tech Center North 7525 East Hampden Avenue Denver, CO 80231	Phone: (303) 696-6644 https://embassysuites3.hilton.com/en/hotels/colorado/embassy-suites-by-hilton-denver-tech-center-north-DENHPES/index.html
----------------------------	--	---

Parking at the Seminar	There is no parking charge for our seminar participants
-------------------------------	---

Driving Directions	Take I-70 West to I-225 South. Travel approximately 10 miles. Exit at Yosemite Street and take a right. Left on Hampden Avenue. Go 1.5 miles to Roslyn Street. Right on Roslyn Street to the hotel
---------------------------	--

Seminar Agenda and Syllabus Information	Registration and breakfast begin at 7:30 a.m. in the Yosemite Room . Please check signage for any last minute room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. Wi-Fi will be available without charge.
--	--

7:30 am	<i>Registration, Continental Breakfast & View Exhibits</i>
8:00 am	Opening Comments and Pre-Test
8:20 am	End Stage Liver Disease: Treatment, Managing Complications and Transplant <ul style="list-style-type: none"> • Staging, workup, and diagnosis of cirrhosis • Medical care of the patient with end stage liver disease Liver Transplantation <ul style="list-style-type: none"> • Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy
9:25 am	Hepatocellular Carcinoma (HCC) <ul style="list-style-type: none"> • Screening diagnostic serum assays and imaging tests • Diagnosis without histology • Treatment and management options: Ablation, TACE and Surgery
10:00 am	<i>Break & View Exhibits</i>
10:15 am	Hepatocellular Carcinoma: New Systemic Treatment Options <ul style="list-style-type: none"> • Current FDA-Approved Therapies • New chemotherapy regimens in development and testing • Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma
11:00 am	Primary Sclerosing Cholangitis (PSC) <ul style="list-style-type: none"> • Epidemiology • Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival •

11:25 am	New Treatments for PBC <ul style="list-style-type: none"> • Causes and Markers of PBC • Treatment management • Ursodeoxycholic Acid (UDCA) and Obeticholic Acid
12:00 pm	<i>Luncheon and Educational Session “LAL-D: Lysosomal Acid Lipase Deficiency- Implementing Rule-out testing in patients with elevated ALT and LDL-C. Hosted by Alexion Pharmaceuticals</i>
12:45 pm	<i>Coffee and Dessert & View Exhibits</i>
1:00 pm	The Best Use of Non-Invasive Diagnostics for Fibrosis Assessment <ul style="list-style-type: none"> • Technologies, Procedures and Outcomes
1:30 pm	NAFLD, LAL-D and NASH <ul style="list-style-type: none"> • Epidemiology, Demographics and Diagnosis • Treatment options for thrombocytopenia; including alternatives to platelet transfusion. • Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult Fatty Liver Disease
2:15 pm	<i>Break & View Exhibits</i>
2:30 pm	NASH Treatments in Practice and in Development <ul style="list-style-type: none"> • Current therapies for NASH • Life style changes as a therapy • Drugs in clinical development for NASH Case Study 3 - NASH Diagnosis and Treatment
3:30 pm	Post-test and Wrap-Up

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is received in writing no later than seven days prior to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who “no show.”

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course’s schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

CME Information


Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0 AMA PRA Category 1 Credit(s)**TM.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.1 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-18-1017. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

**Your Seminar
Faculty**



PAUL POCKROS, MD

Paul Pockros joined the gastroenterology/hepatology division at Scripps Clinic, La Jolla, California in 1985, where he is currently the Director of the Liver Disease Center and Director of Clinical Research of the Scripps Translational Science Institute. He is also the President/Founder of SC Liver Research Consortium.

Dr Pockros has over 300 published manuscripts and abstracts in peer-reviewed journals covering areas such as chronic viral hepatitis, liver transplantation, complications of cirrhosis, alcoholic, metabolic and fatty liver diseases, and diagnostic tests for liver disorders.



CLARK KULIG, MD

Clark Kulig is a Transplant Hepatologist at Presbyterian/St. Luke's Transplant Service in Denver. He enjoys a close working relationship with patients in order to help them understand their liver health and options. He is known as an excellent communicator with his patients and referring physicians, and works with his patients giving them an optimal opportunity for multidisciplinary care including transplantation and cancer therapy.

Dr. Kulig grew up in a small town in rural Wisconsin and attended Carleton College and UW Madison Medical School. He learned how to fly fish for salmon and steelhead during Internal Medicine Residency at OHSU in Portland, OR. Clark completed fellowships in Substance Abuse and Gastroenterology/Hepatology at the University of Colorado in Denver.



MICHELE R. BARNETT, PA

Michelle Barnett, PA-C has been with Associates in Gastroenterology since 2001. She worked in Internal Medicine for 14 years prior to joining the GI practice. She obtained her undergraduate degree from Newman University in Wichita, Kansas and her Physician Assistant degree from Wichita State University. Michelle completed her Master's Degree through the University of Nebraska. She is board certified by NCCPA, is an active member of AASLD and ACG. Clinical interests include HCV, HBV and NASH. She has been appointed to the AASLD Ethics committee through 2020.